Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023)Strong year-end cash position of €168.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback